

issued the final rejection. In a unanimous opinion the court found in part that, "DEA had the obligation when it found substantial evidence of broad scale diversion to achieve a more Spartan pipeline, even though this might cause inconveniences to manufacturer and distributor."

Mr. Chairman, just three weeks ago, on October 29, 1976, attorneys for Western Fehr Laboratories and Boehringer-Ingelheim Limited filed with Administrator Bensinger objections to DEA's proposed 1977 production quota for Preludin. Once again an administrative hearing has been demanded by the companies.

Methylphenidate (Ritalin) differs from the other substances under consideration here today. It is not indicated as an anti-obesity drug. Ritalin is described as "effective" in the treatment of minimal brain dysfunction in children and in the treatment of narcolepsy (a form of sleeping sickness). It is considered "possibly effective" for mild depression. It is ironic that under the heading "Adverse Reactions" in the Physicians' Desk Reference